Trials / Not Yet Recruiting
Not Yet RecruitingNCT06717204
Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Vericiguat for Ventricular Remodeling in Patients With Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 210 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vericiguat Oral Tablet [Verquvo] | Vericiguat in addition to conventional treatment |
| DRUG | Prescription Drugs | Conventional treatment only |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2024-12-04
- Last updated
- 2024-12-04
Locations
3 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06717204. Inclusion in this directory is not an endorsement.